Thomas DesChamps
Director/Board Member at Blue Ash Therapeutics LLC
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Gregory D. Flexter | M | 68 |
Blue Ash Therapeutics LLC
Blue Ash Therapeutics LLC BiotechnologyHealth Technology Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies. | 16 years |
Kevin J. Malloy | M | - |
Blue Ash Therapeutics LLC
Blue Ash Therapeutics LLC BiotechnologyHealth Technology Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies. | 16 years |
William Gruver | M | 79 |
Bucknell University
| 31 years |
Rick J. D'Augustine | M | - |
Blue Ash Therapeutics LLC
Blue Ash Therapeutics LLC BiotechnologyHealth Technology Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies. | 15 years |
Stefan Antonsson | M | - |
Blue Ash Therapeutics LLC
Blue Ash Therapeutics LLC BiotechnologyHealth Technology Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies. | - |
Richard D’Augustine | M | - |
Blue Ash Therapeutics LLC
Blue Ash Therapeutics LLC BiotechnologyHealth Technology Blue Ash Therapeutics LLC was formed in December 2008 in Cincinnati to bring a promising cardiovascular drug - azimilide - to market. Azimilide is an oral once-daily cardiac ant arrhythmic (AA) drug for use in patients whose life-threatening arrhythmias require an implantable cardioverter-defibrillator (ICD) as a therapy of last resort. Azimilide became available for license upon Procter and Gamble's strategic exit in 2008 and final sell-off of pharmaceuticals assets to Warner Chilcott in October 2009. Blue Ash Therapeutics was formed by former P&G managers with long experience and extensive knowledge of azimilide and what's needed for its approval and market launch. In the first 13 months of its formation Blue Ash Therapeutics has assembled public and private seed-round investments, has been awarded a Third Frontier (GCIC) funding grant, and has secured global License Agreement with current azimilide owners, Warner Chilcott, PLC. The next major phase for Blue Ash Therapeutics will be securing venture-funding for carrying out a final FDA-required clinical trial of azimilide for marketing approval. Blue Ash Therapeutics seeks to commercialize not only azimilide, but to grow into a Cincinnati-based company specializing in acute-care cardiovascular therapies. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey B. Lane | M | 80 |
Bear Stearns Asset Management, Inc.
Bear Stearns Asset Management, Inc. Investment ManagersFinance Bear Stearns Asset Management Inc (Bear Stearns) is a Private Equity/Venture Capital firm, a subsidiary of The Bear Stearns Cos LLC founded in 1985. The firm is headquartered in the US. | 1 years |
Robert Ryan Teeter | M | - |
Bucknell University
The Leonard N Stern School of Business
| 8 years |
Glenn Perillo | M | - |
The Leonard N Stern School of Business
| 5 years |
Aaron Selig Fink | M | - |
Bear Stearns Asset Management, Inc.
Bear Stearns Asset Management, Inc. Investment ManagersFinance Bear Stearns Asset Management Inc (Bear Stearns) is a Private Equity/Venture Capital firm, a subsidiary of The Bear Stearns Cos LLC founded in 1985. The firm is headquartered in the US. | 2 years |
Scott Matthew Ogur | M | 52 |
The Leonard N Stern School of Business
Bucknell University
| 7 years |
Richard Suth | M | 56 |
Bucknell University
The Leonard N Stern School of Business
| 7 years |
Xuan Sun | M | 48 |
The Leonard N Stern School of Business
| 6 years |
Christopher S. Reich | M | - |
Bucknell University
The Leonard N Stern School of Business
| 7 years |
Thomas Lee | M | - |
The Leonard N Stern School of Business
| 8 years |
Alan Bazaar | M | 54 |
Bucknell University
The Leonard N Stern School of Business
| 7 years |
Chin Jonathan | M | - |
The Leonard N Stern School of Business
| 4 years |
Nick Markola | M | - |
The Leonard N Stern School of Business
| 3 years |
Matthew Gilfillan | M | - |
Bucknell University
| 4 years |
Mark Forman | M | - |
The Leonard N Stern School of Business
| 2 years |
Craig Steward Lottner | M | - |
The Leonard N Stern School of Business
| 2 years |
Lewis Silberman | M | 45 |
The Leonard N Stern School of Business
| 4 years |
Arun Sharma | M | - |
The Leonard N Stern School of Business
| 4 years |
Chris Tackney | M | - |
Bucknell University
| 4 years |
Ethan Beard | M | - |
The Leonard N Stern School of Business
| 2 years |
Jonathan Root | M | - |
The Leonard N Stern School of Business
| 2 years |
Eric Guzman | M | - |
The Leonard N Stern School of Business
| 4 years |
Jing Wei Zhang | M | 56 |
The Leonard N Stern School of Business
| 4 years |
Sally Blount | M | 62 |
The Leonard N Stern School of Business
| 9 years |
Aaron Marc Rosen | M | - |
The Leonard N Stern School of Business
| 4 years |
Mercedes Locilento | F | - |
Bucknell University
| 4 years |
Christopher Callesano | M | 50 |
The Leonard N Stern School of Business
| 2 years |
John Briggs | M | - |
Bucknell University
| 4 years |
Joseph S. Berry | M | - |
Bucknell University
| 4 years |
Carlos Ricardo Cabana | M | - |
Bucknell University
| 4 years |
Jim Johnson | M | - |
The Leonard N Stern School of Business
| 4 years |
Chris Ling | M | - |
The Leonard N Stern School of Business
| 3 years |
Vishal Sheth | M | - |
The Leonard N Stern School of Business
| 4 years |
Keith Anthony Dubauskas | M | - |
The Leonard N Stern School of Business
| 5 years |
William Conkling | M | 53 |
The Leonard N Stern School of Business
| 2 years |
Fabrizio Arengi Bentivoglio | M | 60 |
The Leonard N Stern School of Business
| 5 years |
Douglas A. Hand | M | - |
The Leonard N Stern School of Business
| 2 years |
Alec Levine | M | - |
Bucknell University
| 4 years |
steven cohen | M | - |
The Leonard N Stern School of Business
| 4 years |
Kristin H. Ribic | F | - |
The Leonard N Stern School of Business
| 2 years |
Thomas Harris | M | - |
The Leonard N Stern School of Business
| 4 years |
Paul Pozin | M | - |
The Leonard N Stern School of Business
| 4 years |
Amit Anand Rathi | M | 49 |
The Leonard N Stern School of Business
| 2 years |
Karina Bubeck | F | - |
The Leonard N Stern School of Business
| 2 years |
Jason Hammerman | M | - |
The Leonard N Stern School of Business
| 4 years |
Lewis I. Brown | M | - |
The Leonard N Stern School of Business
| 4 years |
Karen Ghaffari | F | - |
Bucknell University
| 4 years |
Andrea Clarke Hall | F | - |
The Leonard N Stern School of Business
| 3 years |
Groner eli | M | - |
The Leonard N Stern School of Business
| 2 years |
Mark Cabato | M | - |
Bucknell University
| 4 years |
Jack Mui | M | - |
The Leonard N Stern School of Business
| 4 years |
Thomas James Martin | M | - |
Bucknell University
| 4 years |
Ryan Smith | M | - |
Bucknell University
| 4 years |
Scott W. Searle | M | - |
Bucknell University
| 4 years |
Theodore Janowsky | M | - |
Bucknell University
| 4 years |
Anna Andreeva | F | - |
The Leonard N Stern School of Business
| 2 years |
Jason Finger | M | - |
The Leonard N Stern School of Business
| 30 years |
Douglas Rust Waage | M | - |
Bucknell University
| 4 years |
Andrew West | M | - |
The Leonard N Stern School of Business
| 2 years |
John Dawson | M | - |
Bucknell University
| 4 years |
Mikal Patel | M | - |
The Leonard N Stern School of Business
| 4 years |
Michael Eric Maestas | M | - |
Bucknell University
| 4 years |
Hui Shao | M | 55 |
The Leonard N Stern School of Business
| 2 years |
Christian Dalum | M | 56 |
The Leonard N Stern School of Business
| 2 years |
Nicole Decker | F | - |
The Leonard N Stern School of Business
| 2 years |
Justin Pollack | M | - |
The Leonard N Stern School of Business
| 4 years |
Alexander D. Ryer | M | - |
Bucknell University
| 5 years |
Bo Fifer | M | - |
Bucknell University
| 4 years |
Jeffrey Stephen Gallo | M | - |
The Leonard N Stern School of Business
| 4 years |
Heather Flick McMeekin | F | - |
The Leonard N Stern School of Business
| 2 years |
Wendy Quest Trevisani | F | - |
Bucknell University
| 4 years |
Alexandre Macedo | M | 47 |
The Leonard N Stern School of Business
| 4 years |
Linda Chiu | F | - |
The Leonard N Stern School of Business
| 2 years |
Chris Jennings | M | - |
The Leonard N Stern School of Business
| 3 years |
Eugene Dozortsev | M | 40 |
The Leonard N Stern School of Business
| 4 years |
Chuck Gabler | M | - |
Bucknell University
| 4 years |
Mark Morgan | M | - |
The Leonard N Stern School of Business
| 3 years |
Robert M. Foresman | M | 56 |
Bucknell University
| 4 years |
Scott A. Brown | M | - |
Bucknell University
| 14 years |
Peter Larsen | M | - |
Bucknell University
| 4 years |
Paul Anthony Zummo | M | - |
The Leonard N Stern School of Business
| 4 years |
Peter A. Schwartzman | M | - |
The Leonard N Stern School of Business
| 4 years |
Jason Glazer | M | - |
Bucknell University
| 4 years |
Michael Wang | M | - |
The Leonard N Stern School of Business
| 4 years |
Jeff Graf | M | - |
Bucknell University
| 4 years |
Joseph R. Taylor | M | - |
The Leonard N Stern School of Business
| 3 years |
Alan Kirshenbaum | M | 52 |
The Leonard N Stern School of Business
| 3 years |
Roger J. Braunfeld | M | - |
Bucknell University
| 4 years |
Robby Abraham | M | - |
The Leonard N Stern School of Business
| 4 years |
Dan Whalen | M | - |
Bucknell University
| 4 years |
Shaun R. Gordon | M | - |
The Leonard N Stern School of Business
| 3 years |
Thomas V. Buttacavoli | M | 46 |
The Leonard N Stern School of Business
| 4 years |
Michael J. Diver | M | - |
Bucknell University
| 4 years |
David Leong | M | - |
The Leonard N Stern School of Business
| 4 years |
Gu Xiao Dan | M | 41 |
The Leonard N Stern School of Business
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas DesChamps
- Personal Network